Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

44° Sunny

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

331.48 +8.19 (+2.53%)

Streaming Delayed Price Updated: 2:52 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

November 26, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

November 06, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 06, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine ↗

September 04, 2024

Via Benzinga

What 6 Analyst Ratings Have To Say About Praxis Precision Medicine ↗

August 05, 2024

Via Benzinga

Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews ↗

June 18, 2024

Via Benzinga

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

November 01, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

September 26, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

September 05, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 04, 2024

Via Benzinga

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

September 04, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug ↗

September 03, 2024

Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction...

Via Benzinga

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

September 03, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

September 02, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results ↗

August 14, 2024

Via Benzinga

PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 13, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

August 05, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Are We Having Fun Yet? Stocks Sell Off On Massive Volume ↗

August 03, 2024

In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar.

Via Talk Markets

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗

July 09, 2024

Via Benzinga

Quarterly & Long-Term Portfolios For The Win ↗

July 06, 2024

What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade.

Via Talk Markets

Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst ↗

June 24, 2024

Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures.

Via Benzinga

Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure ↗

June 20, 2024

The companies are working on treatments for essential tremor, a tricky indication.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 04, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 31, 2024

Via Benzinga

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

May 17, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know ↗

May 16, 2024

Via Benzinga

PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024 ↗

May 13, 2024

PRAX stock results show that Praxis Precision Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: vctr@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

All News about Praxis Precision Medicines, Inc. - Common Stock

Sections

Services

Follow Us